Androudi S, Dastiridou A, Pharmakakis N et al (2016) Guidelines for the management of wet age-related macular degeneration: recommendations from a panel of Greek experts. Adv Ther 33(5):715–726
Article CAS PubMed PubMed Central Google Scholar
Arditi A, Cagenello R (1993) On the statistical reliability of letter-chart visual acuity measurements. Invest Ophthalmol Vis Sci 34(1):120–129
Bennett SR, Folk JC, Blodi CF, Klugman M (1990) Factors prognostic of visual outcome in patients with subretinal hemorrhage. Am J Ophthalmol 109(1):33–37
Article CAS PubMed Google Scholar
Bopp S (2012) Subretinal hemorrhage. Natural course and staging. Ophthalmol Z Dtsch Ophthalmol Ges 109:635–643
Boyer DS, Yoon YH, Belfort R Jr et al (2014) Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121(10):1904–14
Brown DM, Kaiser PK, Michels M et. al. ANCHOR Study Group (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355, 1432–1444
Brown DM, Michels M, Kaiser PK et al (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116:57–65
Brown DM, Campochiaro PA, Singh RPCRUISE, Investigators, et al (2010) Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117(6):1124–1133
Brown DM, Heier JS, Clark WL et al (2013) Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 155(3):429–437
Article CAS PubMed Google Scholar
Brown DM, Nguyen QD, Marcus DM, RIDE and RISE Research Group et al (2013) Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 120(10):2013–2022
Brown DM, Schmidt-Erfurth U, Do DV et al (2015) Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology 122(10):2044–2052
Brunner E, Konietschke F, Pauly M, Puri ML (2017) Rank-based procedures in factorial designs: hypotheses about non-parametric treatment effects. J Royal Stat Soc: Ser B (Statistical Methodology) 79(5):1463–1485
Campochiaro PA, Heier JS, Feiner L et al (2010) BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion six-month primary end point results of a phase III study. Ophthalmology 117(6):1102–1112
Clark WL, Boyer DS, Heier JS et al (2016) Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology 123(2):330–336
Deutsche OphthalmologischeGesellschaft (DOG), RetinologischeGesellschaft e. V. (RG), Berufsverband der AugenärzteDeutschlands e. V. (BVA) (2020) Statement of the German Ophthalmological Society (DOG), the Retinological Society (RG) and the Professional Association of German Ophthalmologists (BVA) on anti-VEGF treatment in neovascular age-related macular degeneration : status February 2020. Ophthalmologe 117:746–754
Deutsche OphthalmologischeGesellschaft (DOG), RetinologischeGesellschaft e. V. (RG), Berufsverband der AugenärzteDeutschlands e. V (2020) Statement of the German Ophthalmological Society, the Retinological Society and the Professional Association of Ophthalmologists in Germany on treatment of diabetic macular edema : situation August 2019. Ophthalmologe 117:218–247
Dugel PU, Koh A, Ogura Y et al (2019) HAWK and HARRIER Study Investigators. HAWK and HARRIER phase 3 multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 127(1):72–84
Dugel PU, Koh A, Ogura Y et al (2020) HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 127(1):72–84
Dugel PU, Singh RP, Koh A et al (2020) HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 128(1):89–99
Dugel PU, Singh RP, Koh A et al (2021) HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 128(1):89–99
Germany Ophthalmology Society, Retina Society, Professional Asociation of German Ophthalmologists (2012) Statement of the German Ophthalmology Society, the Retina Society and the Professional Association of German Ophthalmologists for the treatment of macular edema in retinal vein occlusion: therapeutic strategies. Ophthalmologe 109:818–831
Heier JS, Brown DM, Chong V et al (2012) VIEW 1 and VIEW 2 Study Groups Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119(12):2537–2548
Heier JS, Clark WL, Boyer DS et al (2014) Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology 121(7):1414–1420
Heier JS, Korobelnik JF, Brown DM et al (2016) Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology 123(11):2376–2385
Heier JS, Khanani AM, Quezada Ruiz C et al (2022) TENAYA and LUCERNE Investigators Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 399(10326):729–740
Article CAS PubMed Google Scholar
Heimes B, Schick T, Brinkmann CK et al (2016) Design des ORCA-Moduls der OCEAN-Studie: evaluierung der SD-OCT-Befunderhebung in der täglichen Praxisroutine [Design of the ORCA module in the OCEAN study: evaluation of SD-OCT results in daily routine practice]. Ophthalmologe 113(7):570–580
Article CAS PubMed Google Scholar
Holz FG, Roider J, Ogura Y et al (2013) VEGF trap-eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol 97(3):278–284
Korobelnik JF, Do DV, Schmidt-Erfurth U et al (2014) Intravitreal aflibercept for diabetic macular edema. Ophthalmology 121(11):2247–54
Korobelnik JF, Holz FG, Roider J et al (2013) GALILEO Study Group. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. Ophthalmology 121(1):202–208
Lange C, Feltgen N, Junker B, et. al. (2009) Resolving the clinical acuity categories “hand motion” and “counting fingers” using the Freiburg Visual Acuity Test (FrACT). Graefes Arch Clin Exp Ophthalmol 247:137–142
Article CAS PubMed Google Scholar
Loumann KL (2003) Visual acuity testing in diabetic subjects: the decimal progression chart versus the Freiburg visual acuity test. Graefes Arch Clin Exp Ophthalmol 241(8):615–618
Mitchell P, Bandello F, Schmidt-Erfurth U et al (2011) RESTORE Study Group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 118(4):615–25
Nguyen QD, Brown DM, Marcus DM et al (2012) RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119(4):789–801
Ogura Y, Roider J, Korobelnik JF et al (2014) GALILEO Study Group. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am J Ophthalmol 158(5):1032–8
Article CAS PubMed Google Scholar
Radner W, Willinger U, Obermayer W et al (1998) Eine neue Lesetafel zur gleichzeitigen Bestimmung von Lesevisus und Lesegeschwindigkeit [A new reading chart for simultaneous determination of reading vision and reading speed]. Klin Monbl Augenheilkd 213(3):174–181
Article CAS PubMed Google Scholar
Riedl S, Vogl WD, Waldstein SM et al (2022) Impact of intra- and subretinal fluid on vision based on volume quantification in the HARBOR trial. Ophthalmol Retina 6(4):291–297
Rosenfeld PJ, Brown DM, Heier JS et al (2006) MARINA Study Group: ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431
Article CAS PubMed Google Scholar
Schmidt-Erfurth U, Chong V, Loewenstein A et al (2014) European Society of Retina Specialists. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol 98(9):1144–67
Schulze-Bonsel K, Feltgen N, Burau H et al (2006) Visual Acuities “Hand Motion” and “Counting Fingers” can be quantified with the Freiburg visual acuity test. Invest Ophthalmol Vis Sci 47:1236
Take P, Dittmann CA, Mackerodt L et al (2021) Das modifizierte treat-and-extend-schema mit injektionsblöcken in der IVOM-therapie: retrospektive analyse aus der täglichen klinischen anwendung [The modified treat and extend scheme with injection blocks in intravitreal injection treatment : retrospective analysis from the routine clinical application]. Ophthalmologe 118(6):578–586
Article CAS PubMed Google Scholar
Wykoff CC, Abreu F, Adamis AP et al (2022) YOSEMITE and RHINE Investigators. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet 399(10326):741–755
Article CAS PubMed Google Scholar
Wolfram C, Pfeiffer N (2012)Weißbuch zur Situation der ophthalmologischen Versorgung in Deutschland,München
Ziemssen F, Eter N, Fauser S et al (2015) Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany: treatment reality of ranibizumab for neovascular AMD in Germany. Ophthalmologe 112(3):246–54
留言 (0)